The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Open accessAbstract
Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“The tremendous success of the vaccines from Pfizer-BioNTech (BNT162b2, also known as Comirnaty ) [1] and Moderna (mRNA1273, also known as Spikevax ) [2] in combatting COVID-19 has demonstrated the value and rapid translational potential of lipid nanoparticles (LNPs).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“The tremendous success of the vaccines from Pfizer-BioNTech (BNT162b2, also known as Comirnaty ) [1] and Moderna (mRNA1273, also known as Spikevax ) [2] in combatting COVID-19 has demonstrated the value and rapid translational potential of lipid nanoparticles (LNPs).”
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“One example is liposomal doxorubicin, also called Doxil , the first FDA-approved nanomedicine [16], which contains hydrogenated soy phosphatidylcholine (mainly DSPC), cholesterol, and PEG-lipid at a 56:38:5 molar ratio [17]).”
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“Many informative reviews about employing LNPs for vaccines and gene therapy [8,9] have largely focused on how nucleic acid cargo elicits biological changes and enacts therapeutic effects, with less attention to the LNP.”
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Su, K., Shi, L., Sheng, T., Yan, X., Lin, L., Meng, C., Wu, S., Chen, Y., Zhang, Y., Wang, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50093-7 · Cited by 264
Isaac, I., Patel, L., Tran, N., Singam, A., Yun, D., Guha, P., Park, S., & Bhattacharya, C. (2025) · Advanced Materials · doi:10.1002/adma.202507657 · Cited by 33
A general genome editing strategy using CRISPR lipid nanoparticle spherical nucleic acids
Han, Z., Huang, C., Luo, T., & Mirkin, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426094122 · Cited by 17
Li, P., Dong, Z., Jiang, Q., Yu, C., Liu, Y., Yuan, R., Qiu, Y., Meng, T., Hu, F., & Yuan, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114406 · Cited by 6
Ghosh, S., Fan, Y., Laufer, B. I., Stephenson, W., Zang, N., Lawrence, J., Lin, H. H., Sen, S., Miller, S. E., Chu, S., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100303 · Cited by 3
Enhancement of mRNA translation efficiency through 5’-UTR engineering
Broset, E., Blasco-Machín, I., Lampaya, V., Matute, C., Toro-Córdova, A., & Martínez-Oliván, J. (2025) · doi:10.1101/2025.09.30.679448
Metadata
- Authors
- Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 188
- Pages
- 114416
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4283803576
- Cited by
- 1,185
- References
- 120
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.